Biohaven (BHVN) Reports First Patient Enrollment in Phase 3 Generalized Anxiety Disorder Trial Of Troriluzole
Tweet Send to a Friend
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has enrolled its first patient in a Phase 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
